S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:JAZZ

Jazz Pharmaceuticals - JAZZ Competitors

$141.28
+3.83 (+2.79%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$135.90
$142.17
50-Day Range
$133.98
$157.77
52-Week Range
$125.36
$169.98
Volume
478,454 shs
Average Volume
537,850 shs
Market Capitalization
$8.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$204.27

JAZZ vs. PRGO, CORT, HZNP, RDY, TEVA, UTHR, APLS, LEGN, VTRS, and SRPT

Should you be buying Jazz Pharmaceuticals stock or one of its competitors? The main competitors of Jazz Pharmaceuticals include Perrigo (PRGO), Corcept Therapeutics (CORT), Horizon Therapeutics Public (HZNP), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), United Therapeutics (UTHR), Apellis Pharmaceuticals (APLS), Legend Biotech (LEGN), Viatris (VTRS), and Sarepta Therapeutics (SRPT). These companies are all part of the "pharmaceutical preparations" industry.

Jazz Pharmaceuticals vs.

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Perrigo (NYSE:PRGO) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, community ranking, dividends, risk and profitability.

Jazz Pharmaceuticals has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.79, suggesting that its share price is 21% less volatile than the S&P 500.

In the previous week, Jazz Pharmaceuticals had 3 more articles in the media than Perrigo. MarketBeat recorded 9 mentions for Jazz Pharmaceuticals and 6 mentions for Perrigo. Jazz Pharmaceuticals' average media sentiment score of 0.96 beat Perrigo's score of 0.39 indicating that Jazz Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Jazz Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Perrigo
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Jazz Pharmaceuticals received 310 more outperform votes than Perrigo when rated by MarketBeat users. Likewise, 80.40% of users gave Jazz Pharmaceuticals an outperform vote while only 66.97% of users gave Perrigo an outperform vote.

CompanyUnderperformOutperform
Jazz PharmaceuticalsOutperform Votes
1058
80.40%
Underperform Votes
258
19.60%
PerrigoOutperform Votes
748
66.97%
Underperform Votes
369
33.03%

89.8% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 94.1% of Perrigo shares are owned by institutional investors. 4.4% of Jazz Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Perrigo has a net margin of -2.91% compared to Jazz Pharmaceuticals' net margin of -6.12%. Jazz Pharmaceuticals' return on equity of 24.04% beat Perrigo's return on equity.

Company Net Margins Return on Equity Return on Assets
Jazz Pharmaceuticals -6.12% 24.04% 6.88%
Perrigo -2.91% 5.79% 2.61%

Perrigo has higher revenue and earnings than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Jazz Pharmaceuticals$3.66 billion2.38-$224.06 million-$3.55-38.68
Perrigo$4.45 billion1.00-$140.60 million-$0.96-34.38

Jazz Pharmaceuticals presently has a consensus target price of $204.27, suggesting a potential upside of 48.76%. Perrigo has a consensus target price of $48.00, suggesting a potential upside of 45.45%. Given Jazz Pharmaceuticals' higher probable upside, equities research analysts clearly believe Jazz Pharmaceuticals is more favorable than Perrigo.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Jazz Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.88
Perrigo
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Jazz Pharmaceuticals beats Perrigo on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JAZZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

JAZZ vs. The Competition

MetricJazz PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$8.70B$5.46B$4.28B$5.84B
Dividend YieldN/A2.58%2.39%4.40%
P/E Ratio-38.683.8194.8611.79
Price / Sales2.38287.143,450.6255.97
Price / Cash6.3319.7427.13103.34
Price / Book2.804.124.434.91
Net Income-$224.06M$185.90M$114.82M$190.66M
7 Day Performance1.61%-2.06%-1.44%-0.07%
1 Month Performance-4.54%-9.22%-7.18%-6.56%
1 Year Performance-13.97%-16.11%-17.15%-19.53%

Jazz Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PRGO
Perrigo
3.0603 of 5 stars
$33.98
-1.7%
$48.00
+41.3%
-12.1%$4.58B$4.45B-35.408,900
CORT
Corcept Therapeutics
2.4556 of 5 stars
$20.84
-1.9%
$28.50
+36.8%
-12.8%$2.25B$401.86M23.68238Positive News
HZNP
Horizon Therapeutics Public
2.2623 of 5 stars
$107.32
-1.7%
$111.42
+3.8%
-0.6%$24.52B$3.63B48.132,115
RDY
Dr. Reddy's Laboratories
1.9804 of 5 stars
$54.36
0.0%
$67.00
+23.3%
+2.4%$9.06B$237.28B20.1324,795
TEVA
Teva Pharmaceutical Industries
1.7486 of 5 stars
$8.73
-0.8%
$10.78
+23.5%
+5.2%$9.70B$14.93B-4.1236,826
UTHR
United Therapeutics
2.9883 of 5 stars
$212.99
-4.2%
$291.55
+36.9%
+21.5%$9.86B$1.94B14.18965Insider Selling
News Coverage
APLS
Apellis Pharmaceuticals
2.5797 of 5 stars
$61.21
-1.4%
$78.40
+28.1%
+19.6%$6.81B$75.42M-9.99476Insider Selling
LEGN
Legend Biotech
1.3723 of 5 stars
$43.66
-2.9%
$69.33
+58.8%
+17.4%$6.74B$89.79M-29.501,071Analyst Report
News Coverage
VTRS
Viatris
2.709 of 5 stars
$9.40
-2.6%
$13.50
+43.6%
-15.4%$11.25B$16.26B5.5037,000Options Volume
SRPT
Sarepta Therapeutics
2.4528 of 5 stars
$129.11
-1.6%
$165.88
+28.5%
+60.2%$11.36B$933.01M-16.081,162Analyst Report
This page (NASDAQ:JAZZ) was last updated on 3/24/2023 by MarketBeat.com Staff